C WorldWide Group Holding A S Sells 22,381 Shares of Sarepta Therapeutics Inc (SRPT)

Share on StockTwits

C WorldWide Group Holding A S reduced its stake in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 32.2% during the third quarter, Holdings Channel reports. The institutional investor owned 47,046 shares of the biotechnology company’s stock after selling 22,381 shares during the quarter. C WorldWide Group Holding A S’s holdings in Sarepta Therapeutics were worth $7,598,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in SRPT. Waddell & Reed Financial Inc. bought a new position in shares of Sarepta Therapeutics during the second quarter valued at about $103,682,000. Millennium Management LLC grew its stake in shares of Sarepta Therapeutics by 242.2% during the second quarter. Millennium Management LLC now owns 858,407 shares of the biotechnology company’s stock valued at $113,464,000 after buying an additional 607,588 shares during the last quarter. American Century Companies Inc. bought a new position in shares of Sarepta Therapeutics during the third quarter valued at about $65,705,000. Boxer Capital LLC bought a new position in shares of Sarepta Therapeutics during the second quarter valued at about $49,568,000. Finally, Macquarie Group Ltd. grew its stake in shares of Sarepta Therapeutics by 444.0% during the second quarter. Macquarie Group Ltd. now owns 383,093 shares of the biotechnology company’s stock valued at $50,637,000 after buying an additional 312,670 shares during the last quarter. 89.84% of the stock is currently owned by hedge funds and other institutional investors.

Shares of SRPT opened at $137.18 on Wednesday. The company has a quick ratio of 7.84, a current ratio of 8.85 and a debt-to-equity ratio of 0.65. Sarepta Therapeutics Inc has a one year low of $50.51 and a one year high of $176.50. The stock has a market capitalization of $9.75 billion, a price-to-earnings ratio of -83.65 and a beta of 1.59.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, October 24th. The biotechnology company reported ($1.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by ($0.29). Sarepta Therapeutics had a negative return on equity of 23.67% and a negative net margin of 89.46%. The company had revenue of $78.49 million during the quarter, compared to analysts’ expectations of $78.84 million. Sell-side analysts predict that Sarepta Therapeutics Inc will post -4.38 EPS for the current fiscal year.

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the firm’s stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $140.50, for a total value of $936,713.50. Following the completion of the sale, the director now directly owns 126,534 shares in the company, valued at $17,778,027. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Douglas S. Ingram acquired 16,695 shares of the stock in a transaction on Tuesday, October 30th. The stock was bought at an average price of $120.39 per share, with a total value of $2,009,911.05. Following the completion of the acquisition, the chief executive officer now directly owns 412,811 shares of the company’s stock, valued at $49,698,316.29. The disclosure for this purchase can be found here. Company insiders own 7.90% of the company’s stock.

A number of research analysts have recently issued reports on the company. Citigroup raised their price objective on Sarepta Therapeutics from $174.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday. BidaskClub lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 31st. Piper Jaffray Companies dropped their target price on shares of Sarepta Therapeutics from $189.00 to $168.00 and set an “overweight” rating for the company in a report on Friday, October 26th. Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating and set a $147.00 target price for the company in a report on Tuesday, October 16th. Finally, Sanford C. Bernstein began coverage on shares of Sarepta Therapeutics in a report on Friday, October 12th. They set an “outperform” rating and a $170.00 target price for the company. Three investment analysts have rated the stock with a hold rating, twenty-four have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $169.19.

TRADEMARK VIOLATION NOTICE: “C WorldWide Group Holding A S Sells 22,381 Shares of Sarepta Therapeutics Inc (SRPT)” was published by Week Herald and is owned by of Week Herald. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://weekherald.com/2018/11/07/c-worldwide-group-holding-a-s-sells-22381-shares-of-sarepta-therapeutics-inc-srpt.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

See Also: What is the balance sheet?

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply